Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine-131-SGMIB anti-HER2 monoclonal antibody

Next Previous
Search
Drug Profile

Iodine-131-SGMIB anti-HER2 monoclonal antibody

Alternative Names: 131I-SGMIB anti-HER2-VHH1; [131I]-SGMIB Anti-HER2 VHH1; CAM-H2; CAM-H2-I131; Iodine-131-SGMIB anti-HER2 VHH1

Latest Information Update: 17 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Camel-IDS
  • Developer Precirix
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Iodine radioisotopes; Monoclonal antibodies; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
  • No development reported Breast cancer

Most Recent Events

  • 10 Jun 2024 Efficacy and safety data from a phase-I/II trial in Oesophageal cancer, Gastric cancer and HER2-positive breast cancer released by Precirix
  • 14 Sep 2021 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04467515)
  • 04 May 2021 Phase-I/II clinical trials in Gastric cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Canada (IV) (NCT04467515)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top